[go: up one dir, main page]

WO2000038669A3 - Methode de prevention et de traitement de la degeneration des neurones - Google Patents

Methode de prevention et de traitement de la degeneration des neurones Download PDF

Info

Publication number
WO2000038669A3
WO2000038669A3 PCT/US1999/031070 US9931070W WO0038669A3 WO 2000038669 A3 WO2000038669 A3 WO 2000038669A3 US 9931070 W US9931070 W US 9931070W WO 0038669 A3 WO0038669 A3 WO 0038669A3
Authority
WO
WIPO (PCT)
Prior art keywords
degeneration
neurons
treating
preventing
naloxone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/031070
Other languages
English (en)
Other versions
WO2000038669A2 (fr
Inventor
Guoying Bing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Priority to AU23935/00A priority Critical patent/AU2393500A/en
Publication of WO2000038669A2 publication Critical patent/WO2000038669A2/fr
Anticipated expiration legal-status Critical
Publication of WO2000038669A3 publication Critical patent/WO2000038669A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Laminated Bodies (AREA)

Abstract

La présente invention concerne une technique de provocation de symptômes de type Parkinson chez des animaux par injection de lipopolysaccharides dans le locus niger. L'invention concerne en outre une méthode de prévention et de traitement de la dégénération de neurones dans une région du cerveau, notamment la dégénération de neurones dopaminergiques dans le locus niger, associée à la maladie de Parkinson.
PCT/US1999/031070 1998-12-29 1999-12-29 Methode de prevention et de traitement de la degeneration des neurones Ceased WO2000038669A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23935/00A AU2393500A (en) 1998-12-29 1999-12-29 Method for preventing and treating the degeneration of neurons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11421498P 1998-12-29 1998-12-29
US60/114,214 1998-12-29

Publications (2)

Publication Number Publication Date
WO2000038669A2 WO2000038669A2 (fr) 2000-07-06
WO2000038669A3 true WO2000038669A3 (fr) 2001-10-11

Family

ID=22353984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/031070 Ceased WO2000038669A2 (fr) 1998-12-29 1999-12-29 Methode de prevention et de traitement de la degeneration des neurones

Country Status (3)

Country Link
AU (1) AU2393500A (fr)
CO (1) CO5111024A1 (fr)
WO (1) WO2000038669A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151961B1 (en) 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
AU2005244852B2 (en) * 2004-05-12 2011-09-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
CN118845749A (zh) * 2024-07-02 2024-10-29 中国医学科学院药用植物研究所 L-nrb在制备治疗帕金森症的药物中的应用

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
A. CASTAÑO ET AL.: "Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System", JOURNAL OF NEUROCHEMISTRY, vol. 70, no. 4, April 1998 (1998-04-01), pages 1584 - 1592, XP000982792 *
A.M. SZCZEPANIK ET AL.: "EFFECTS OF CHRONIC INTRAHIPPOCAMPAL INFUSION OF LIPOPOLYSACCHARIDE IN THE RAT", NEUROSCIENCE, vol. 70, no. 1, 1996, pages 57 - 65, XP000982798 *
A.M.S. MAYER: "THERAPEUTIC IMPLICATIONS OF MICROGLIA ACTIVATION BY LIPOPOLYSACCHARIDE AND REACTIVE OXYGEN SPECIES GENERATION IN SEPTIC SHOCK AND CENTRAL NERVOUS SYSTEM PATHOLOGIES: A REVIEW", MEDICINA (SHOCK 1998: OXYGEN, NITRIC OXIDE AND THERAPEUTIC PERSPECTIVES, INTERNATIONAL SYMPOSIUM, ACADEMIA NACIONAL DE MEDICINA, BUENES AIRES, 30 APRIL 1998), vol. 58, no. 4, 1998, pages 377 - 385, XP000982794 *
A.P.LIEBERMAN ET AL.: "Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus", PROC. NATL. ACAD. SCI USA, vol. 86, August 1989 (1989-08-01), pages 6348 - 6352, XP000982744 *
AGNOLI, A. ET AL: "Are the enkephalins involved in Parkinson's disease? Clinical and neuroendocrine responses to naloxone administration", ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY, vol. 22, 1980, pages 511 - 521, XP000900514 *
C.N. MONTERO-MENEI ET AL.: "Early events of the inflammatory reaction induced in rat brain by lipopolysaccharide intracerebral injection: relative contribution of peripheral monocytes and activated microglia", BRAIN RESEARCH, vol. 724, no. 1, 10 June 1996 (1996-06-10), pages 55 - 66, XP000982796 *
C.N. MONTERO-MENEI ET AL.: "Lipopolysaccharide intracerebral administration induces minimal inflammatory reaction in rat brain", BRAIN RESEARCH, vol. 653, no. 1-2, 8 August 1994 (1994-08-08), pages 101 - 111, XP000982797 *
CAREY, R.J.: "Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue", LIFE SCIENCES, vol. 48, no. 13, 1991, pages 1303 - 1308, XP000934331 *
DIAMOND, B.I. ET AL: "Enkephalins and nigrostriatal function", NEUROLOGY, vol. 28, no. 11, 1978, pages 1085 - 1088, XP000934332 *
F. CASAMENTI ET AL.: "MORPHOLOGICAL, BIOCHEMICAL AND BEHAVIOURAL CHANGES INDUCED BY NEUROTOXIC AND INFLAMMATORY INSULTS TO THE NUCLEUS BASALIS", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, vol. 16, no. 7-8, November 1998 (1998-11-01) - December 1998 (1998-12-01), pages 705 - 714, XP000982800 *
FEIGENBAUM, J. ETAL: "Possible DA agonist properties of naloxone", INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol. 17, no. 3, 1982, pages 139 - 144, XP000934340 *
G.Y. BING ET AL.: "MICROGLIA MEDIATED DOPAMINERGIC CELL DEATH IN THE SUBSTANTIA NIGRA: A NEW ANIMAL MODEL FOR PARKINSON'S DISEASE", SOCIETY FOR NEUROSCIENCE ABSTRACTS (28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2; LOS ANGELES, CALIFORNIA, USA, NOVEMBER 7-12, 1998), vol. 24, no. 1-2, 1998, pages 1466, XP000982790 *
HAAG, T. ET AL: "Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 90, 1993, pages 6315 - 6319, XP000929833 *
J. LUTHMAN ET AL.: "Effects of the 3-hydroxyanthranilic analogue NCR-631 on anoxia-, IL-1beta- and LPS-induced hippocampal pyramidal cell loss in vitro", AMINO ACIDS, vol. 14, no. 1-3, 1998, pages 263 - 269, XP000982829 *
LIU, B. ET AL: "Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 293, no. 2, May 2000 (2000-05-01), pages 607 - 617, XP000934290 *
LU, X. ET AL: "Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats", NEUROSCIENCE, vol. 97, no. 2, 28 April 2000 (2000-04-28), pages 285 - 291, XP000934248 *
M.M. IRAVANI ET AL.: "DOPAMINE CELL LOSS AND EXPRESSION OF INDUCIBLE NITRIC OXIDE SYNTHASE IMMUNOREACTIVITY FOLLOWING INTRANIGRAL INJECTION OF LIPOPOLYSACCHARIDE", BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. PROC. SUPPL., 8 September 1998 (1998-09-08) - 11 September 1998 (1998-09-11), pages 44P, XP000982795 *
QUOCK, R.M. ET AL: "Potentiation by naloxone of the anti-oxotremorine effect of L-dopa", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 95, no. 3-4, 1983, pages 193 - 198, XP000934329 *
S. MUN-BRYCE ET AL.: "Gelatinase B modulates selective opening of the blood-brain barrier during inflammation", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 274, no. 5 Part 2, May 1998 (1998-05-01), pages R1203 - R1211, XP000982793 *
S.C. LEE ET AL.: "Cytokine Production by Human Fetak Microglia and Astrocytes", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 7, 1 April 1993 (1993-04-01), pages 2659 - 2667, XP000982745 *
S.F. SHARIF ET AL.: "Human astrocyte production of tumour necrosis factor.alpha, interleukin-1beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin", NEUROL.RES., vol. 15, no. 2, April 1993 (1993-04-01), pages 109 - 112, XP000979390 *
SANDYK, R. ET AL: "Naloxone treatment of L-dopa induced dyskinesias in Parkinson's disease", THE AMERICAN JOURNAL OF PSYCHIATRY, vol. 143, no. 1, 1986, pages 118, XP000934289 *
TRABUCCHI, M. ET AL: "Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy", ARCHIVES OF NEUROLOGY, vol. 39, no. 2, 1982, pages 120 - 121, XP000934326 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients
US7151961B1 (en) 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
US8401634B2 (en) 2002-05-24 2013-03-19 Boston Scientific Neuromodulation Corporation Treatment of movement disorders by brain stimulation

Also Published As

Publication number Publication date
AU2393500A (en) 2000-07-31
CO5111024A1 (es) 2001-12-26
WO2000038669A2 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
IL159324A0 (en) Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease
WO1997034586A3 (fr) Dispositif et methode de traitement de maladies ophtalmiques
WO2001012170A3 (fr) Compositions a base de modafinil destinees au traitement du trouble deficitaire de l'attention avec hyperactivite et de la fatigue associee a la sclerose en plaques
EP1466606A3 (fr) Utilisation de l'inosine dans la fabrication d'un medicament pour stimuler l'excroissance des neurons du système nerveux central
ES2168006T3 (es) Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.
WO2002051433A3 (fr) Nouvelle utilisation de l'artemine, membre de la famille de ligands du facteur de croissance gdnf
WO1999045949A3 (fr) Utilisation de la follistatine pour moduler gdf-8 et bmp-11
WO2003011104A3 (fr) Dispositif et procede permettant de modifier l'activite cerebrale essentielle a l'aide d'une lumiere et d'un son
WO2000050568A3 (fr) Transplantation de cellules hematopoietiques
AU2003296341A8 (en) System and method for treating Parkinson's Disease and other movement disorders
AU1645995A (en) Leather treatment process for leather coloring, leather coloring process performed on leather thereby treated, and leather article produced by the leather coloring process
WO2002049626A3 (fr) Nouveau traitement
WO2000038669A3 (fr) Methode de prevention et de traitement de la degeneration des neurones
WO2002056745A3 (fr) Methode de traitement de la maladie de parkinson
WO2001007026A3 (fr) Methode de traitement amelioree du diabete de type ii et de l'obesite
CA2347863A1 (fr) Traitement des affections de la retine
WO1999048489A3 (fr) Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
AUPP674898A0 (en) A method of treatment
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
WO1999059563A3 (fr) Cabergoline et pramipexole: nouvelles utilisations et combinaisons
AU4316600A (en) Human brain carboxypeptidase b
WO2004056768A3 (fr) Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
CA2246560A1 (fr) Methodes d'administration d'un antagoniste du recepteur ampa pour traiter les dyskinesies associees a la therapie par un agoniste de la dopamine
JP2000352566A5 (fr)
AU6258798A (en) Facilitation of repair of neural injury with cm101/gbs toxin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase